Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

CD36 deficiency attenuates experimental mycobacterial infection

Authors: Michael Hawkes, Xiaoming Li, Maryanne Crockett, Angelina Diassiti, Constance Finney, Gundula Min-Oo, W Conrad Liles, Jun Liu, Kevin C Kain

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Members of the CD36 scavenger receptor family have been implicated as sensors of microbial products that mediate phagocytosis and inflammation in response to a broad range of pathogens. We investigated the role of CD36 in host response to mycobacterial infection.

Methods

Experimental Mycobacterium bovis Bacillus Calmette-Guérin (BCG) infection in Cd36 +/+ and Cd36 -/- mice, and in vitro co-cultivation of M. tuberculosis, BCG and M. marinum with Cd36 +/+ and Cd36 -/- murine macrophages.

Results

Using an in vivo model of BCG infection in Cd36 +/+ and Cd36 -/- mice, we found that mycobacterial burden in liver and spleen is reduced (83% lower peak splenic colony forming units, p < 0.001), as well as the density of granulomas, and circulating tumor necrosis factor (TNF) levels in Cd36 -/- animals. Intracellular growth of all three mycobacterial species was reduced in Cd36 -/- relative to wild type Cd36 +/+ macrophages in vitro. This difference was not attributable to alterations in mycobacterial uptake, macrophage viability, rate of macrophage apoptosis, production of reactive oxygen and/or nitrogen species, TNF or interleukin-10. Using an in vitro model designed to recapitulate cellular events implicated in mycobacterial infection and dissemination in vivo (i.e., phagocytosis of apoptotic macrophages containing mycobacteria), we demonstrated reduced recovery of viable mycobacteria within Cd36 -/- macrophages.

Conclusions

Together, these data indicate that CD36 deficiency confers resistance to mycobacterial infection. This observation is best explained by reduced intracellular survival of mycobacteria in the Cd36 -/- macrophage and a role for CD36 in the cellular events involved in granuloma formation that promote early bacterial expansion and dissemination.
Appendix
Available only for authorised users
Literature
1.
2.
Saunders BM, Britton WJ: Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol. 2007, 85 (2): 103-111. 10.1038/sj.icb.7100027.CrossRefPubMed
3.
Egen JG, Rothfuchs AG, Feng CG, Winter N, Sher A, Germain RN: Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity. 2008, 28 (2): 271-284. 10.1016/j.immuni.2007.12.010.CrossRefPubMedPubMedCentral
4.
Davis JM, Ramakrishnan L: The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell. 2009, 136 (1): 37-49. 10.1016/j.cell.2008.11.014.CrossRefPubMedPubMedCentral
5.
Lau YL, Chan GC, Ha SY, Hui YF, Yuen KY: The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis. Clin Infect Dis. 1998, 26 (1): 226-227. 10.1086/517036.CrossRefPubMed
6.
Winkelstein JA, Marino MC, Johnston RB, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs H, Quie P, et al: Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000, 79 (3): 155-169. 10.1097/00005792-200005000-00003.CrossRef
7.
Picard C, Fieschi C, Altare F, Al-Jumaah S, Al-Hajjar S, Feinberg J, Dupuis S, Soudais C, Al-Mohsen IZ, Genin E, et al: Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet. 2002, 70 (2): 336-348. 10.1086/338625.CrossRefPubMed
8.
Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, Drysdale P, Jouanguy E, Doffinger R, Bernaudin F, et al: Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998, 280 (5368): 1432-1435. 10.1126/science.280.5368.1432.CrossRefPubMed
9.
Jouanguy E, Lamhamedi-Cherradi S, Altare F, Fondaneche MC, Tuerlinckx D, Blanche S, Emile JF, Gaillard JL, Schreiber R, Levin M, et al: Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J Clin Invest. 1997, 100 (11): 2658-2664. 10.1172/JCI119810.CrossRefPubMedPubMedCentral
10.
Dupuis S, Dargemont C, Fieschi C, Thomassin N, Rosenzweig S, Harris J, Holland SM, Schreiber RD, Casanova JL: Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 2001, 293 (5528): 300-303. 10.1126/science.1061154.CrossRefPubMed
11.
Bellamy R: NRAMP1 and susceptibility to tuberculosis. Int J Tuberc Lung Dis. 2002, 6 (9): 747-PubMed
12.
Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV: Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med. 1998, 338 (10): 640-644. 10.1056/NEJM199803053381002.CrossRefPubMed
13.
Bellamy R, Ruwende C, Corrah T, McAdam KP, Thursz M, Whittle HC, Hill AV: Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis. 1999, 179 (3): 721-724. 10.1086/314614.CrossRefPubMed
14.
Bellamy R, Beyers N, McAdam KP, Ruwende C, Gie R, Samaai P, Bester D, Meyer M, Corrah T, Collin M, et al: Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc Natl Acad Sci USA. 2000, 97 (14): 8005-8009. 10.1073/pnas.140201897.CrossRefPubMedPubMedCentral
15.
Casanova JL, Abel L: Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol. 2002, 20: 581-620. 10.1146/annurev.immunol.20.081501.125851.CrossRefPubMed
16.
Flynn JL: Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect. 2006, 8 (4): 1179-1188. 10.1016/j.micinf.2005.10.033.CrossRefPubMed
17.
Costello RT, Izumi T, Sakurami T: Behavior of attenuated mycobacteria in organs of neonatal and adult mice. J Exp Med. 1971, 134 (2): 366-380. 10.1084/jem.134.2.366.CrossRefPubMedPubMedCentral
18.
Cosma CL, Humbert O, Sherman DR, Ramakrishnan L: Trafficking of superinfecting Mycobacterium organisms into established granulomas occurs in mammals and is independent of the Erp and ESX-1 mycobacterial virulence loci. J Infect Dis. 2008, 198 (12): 1851-1855. 10.1086/593175.CrossRefPubMedPubMedCentral
19.
Kremer L, Estaquier J, Wolowczuk I, Biet F, Ameisen JC, Locht C: Ineffective cellular immune response associated with T-cell apoptosis in susceptible Mycobacterium bovis BCG-infected mice. Infect Immun. 2000, 68 (7): 4264-4273. 10.1128/IAI.68.7.4264-4273.2000.CrossRefPubMedPubMedCentral
20.
Tonjum T, Welty DB, Jantzen E, Small PL: Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA-DNA hybridization, and 16S rRNA gene sequence analysis. J Clin Microbiol. 1998, 36 (4): 918-925.PubMedPubMedCentral
21.
Cosma CL, Sherman DR, Ramakrishnan L: The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol. 2003, 57: 641-676. 10.1146/annurev.micro.57.030502.091033.CrossRefPubMed
22.
Cosma CL, Humbert O, Ramakrishnan L: Superinfecting mycobacteria home to established tuberculous granulomas. Nat Immunol. 2004, 5 (8): 828-835. 10.1038/ni1091.CrossRefPubMed
23.
Cosma CL, Swaim LE, Volkman H, Ramakrishnan L, Davis JM: Zebrafish and frog models of Mycobacterium marinum infection. Curr Protoc Microbiol. 2006, Chapter 10 (Unit 10B): 12-
24.
Decostere A, Hermans K, Haesebrouck F: Piscine mycobacteriosis: a literature review covering the agent and the disease it causes in fish and humans. Vet Microbiol. 2004, 99 (3-4): 159-166. 10.1016/j.vetmic.2003.07.011.CrossRefPubMed
25.
Volkman HE, Clay H, Beery D, Chang JC, Sherman DR, Ramakrishnan L: Tuberculous granuloma formation is enhanced by a mycobacterium virulence determinant. PLoS Biol. 2004, 2 (11): e367-10.1371/journal.pbio.0020367.CrossRefPubMedPubMedCentral
26.
Tan T, Lee WL, Alexander DC, Grinstein S, Liu J: The ESAT-6/CFP-10 secretion system of Mycobacterium marinum modulates phagosome maturation. Cell Microbiol. 2006, 8 (9): 1417-1429. 10.1111/j.1462-5822.2006.00721.x.CrossRefPubMed
27.
van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, Brenner M, Peters PJ: M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell. 2007, 129 (7): 1287-1298. 10.1016/j.cell.2007.05.059.CrossRefPubMed
28.
Febbraio M, Hajjar DP, Silverstein RL: CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001, 108 (6): 785-791.CrossRefPubMedPubMedCentral
29.
Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I: Immunosuppressive effects of apoptotic cells. Nature. 1997, 390 (6658): 350-351. 10.1038/37022.CrossRefPubMed
30.
Stuart LM, Deng J, Silver JM, Takahashi K, Tseng AA, Hennessy EJ, Ezekowitz RA, Moore KJ: Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J Cell Biol. 2005, 170 (3): 477-485. 10.1083/jcb.200501113.CrossRefPubMedPubMedCentral
31.
Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, Sovath S, Shamel L, Hartung T, Zahringer U, et al: CD36 is a sensor of diacylglycerides. Nature. 2005, 433 (7025): 523-527. 10.1038/nature03253.CrossRefPubMed
32.
Baranova IN, Kurlander R, Bocharov AV, Vishnyakova TG, Chen Z, Remaley AT, Csako G, Patterson AP, Eggerman TL: Role of human CD36 in bacterial recognition, phagocytosis, and pathogen-induced JNK-mediated signaling. J Immunol. 2008, 181 (10): 7147-7156.CrossRefPubMedPubMedCentral
33.
Patel SN, Lu Z, Ayi K, Serghides L, Gowda DC, Kain KC: Disruption of CD36 impairs cytokine response to Plasmodium falciparum glycosylphosphatidylinositol and confers susceptibility to severe and fatal malaria in vivo. J Immunol. 2007, 178 (6): 3954-3961.CrossRefPubMed
34.
Serghides L, Smith TG, Patel SN, Kain KC: CD36 and malaria: friends or foes?. Trends Parasitol. 2003, 19 (10): 461-469. 10.1016/j.pt.2003.08.006.CrossRefPubMed
35.
Philips JA, Rubin EJ, Perrimon N: Drosophila RNAi screen reveals CD36 family member required for mycobacterial infection. Science. 2005, 309 (5738): 1251-1253. 10.1126/science.1116006.CrossRefPubMed
36.
Sanchez MD, Garcia Y, Montes C, Paris SC, Rojas M, Barrera LF, Arias MA, Garcia LF: Functional and phenotypic changes in monocytes from patients with tuberculosis are reversed with treatment. Microbes Infect. 2006, 8 (9-10): 2492-2500. 10.1016/j.micinf.2006.06.005.CrossRefPubMed
37.
Sulahian TH, Imrich A, Deloid G, Winkler AR, Kobzik L: Signaling pathways required for macrophage scavenger receptor-mediated phagocytosis: analysis by scanning cytometry. Respir Res. 2008, 9: 59-10.1186/1465-9921-9-59.CrossRefPubMedPubMedCentral
38.
Malo D, Vogan K, Vidal S, Hu J, Cellier M, Schurr E, Fuks A, Bumstead N, Morgan K, Gros P: Haplotype mapping and sequence analysis of the mouse Nramp gene predict susceptibility to infection with intracellular parasites. Genomics. 1994, 23 (1): 51-61. 10.1006/geno.1994.1458.CrossRefPubMed
39.
Kumar S, Lavin MF: The ICE family of cysteine proteases as effectors of cell death. Cell Death Differ. 1996, 3 (3): 255-267.PubMed
40.
Nau GJ, Liaw L, Chupp GL, Berman JS, Hogan BL, Young RA: Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect Immun. 1999, 67 (8): 4223-4230.PubMedPubMedCentral
41.
Bhatt K, Salgame P: Host Innate Immune Response to Mycobacterium tuberculosis. J Clin Immunol. 2007, 27 (4): 347-362. 10.1007/s10875-007-9084-0.CrossRefPubMed
42.
Wintergerst ES, Jelk J, Rahner C, Asmis R: Apoptosis induced by oxidized low density lipoprotein in human monocyte-derived macrophages involves CD36 and activation of caspase-3. Eur J Biochem. 2000, 267 (19): 6050-6059. 10.1046/j.1432-1327.2000.01682.x.CrossRefPubMed
43.
Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG: Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol. 1998, 161 (5): 2636-2641.PubMed
44.
Loeuillet C, Martinon F, Perez C, Munoz M, Thome M, Meylan PR: Mycobacterium tuberculosis subverts innate immunity to evade specific effectors. J Immunol. 2006, 177 (9): 6245-6255.CrossRefPubMed
45.
Winau F, Weber S, Sad S, de Diego J, Hoops SL, Breiden B, Sandhoff K, Brinkmann V, Kaufmann SH, Schaible UE: Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity. 2006, 24 (1): 105-117. 10.1016/j.immuni.2005.12.001.CrossRefPubMed
46.
Chan ED, Chan J, Schluger NW: What is the role of nitric oxide in murine and human host defense against tuberculosis?Current knowledge. Am J Respir Cell Mol Biol. 2001, 25 (5): 606-612.CrossRefPubMed
47.
Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991, 43 (2): 109-142.PubMed
48.
Heldwein KA, Liang MD, Andresen TK, Thomas KE, Marty AM, Cuesta N, Vogel SN, Fenton MJ: TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol. 2003, 74 (2): 277-286. 10.1189/jlb.0103026.CrossRefPubMed
49.
Sugawara I, Yamada H, Li C, Mizuno S, Takeuchi O, Akira S: Mycobacterial infection in TLR2 and TLR6 knockout mice. Microbiol Immunol. 2003, 47 (5): 327-336.CrossRefPubMed
50.
Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA, Barnes PF, Rollinghoff M, Bolcskei PL, Wagner M, et al: Induction of direct antimicrobial activity through mammalian toll-like receptors. Science. 2001, 291 (5508): 1544-1547. 10.1126/science.291.5508.1544.CrossRefPubMed
51.
Rojas-Espinosa O, Wek-Rodriguez K, Arce-Paredes P, Aguilar-Torrentera F, Truyens C, Carlier Y: Contrary to BCG, MLM fails to induce the production of TNF alpha and NO by macrophages. Int J Lepr Other Mycobact Dis. 2002, 70 (2): 111-118.PubMed
52.
Gordon AH, Hart PD: Stimulation or inhibition of the respiratory burst in cultured macrophages in a mycobacterium model: initial stimulation is followed by inhibition after phagocytosis. Infect Immun. 1994, 62 (10): 4650-4651.PubMedPubMedCentral
53.
Bellamy R: The natural resistance-associated macrophage protein and susceptibility to intracellular pathogens. Microbes Infect. 1999, 1 (1): 23-27. 10.1016/S1286-4579(99)80010-0.CrossRefPubMed
54.
Flesch IE, Hess JH, Oswald IP, Kaufmann SH: Growth inhibition of Mycobacterium bovis by IFN-gamma stimulated macrophages: regulation by endogenous tumor necrosis factor-alpha and by IL-10. Int Immunol. 1994, 6 (5): 693-700. 10.1093/intimm/6.5.693.CrossRefPubMed
55.
Murray PJ, Wang L, Onufryk C, Tepper RI, Young RA: T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol. 1997, 158 (1): 315-321.PubMed
56.
Murray PJ, Young RA: Increased antimycobacterial immunity in interleukin-10-deficient mice. Infect Immun. 1999, 67 (6): 3087-3095.PubMedPubMedCentral
57.
Jacobs M, Brown N, Allie N, Gulert R, Ryffel B: Increased resistance to mycobacterial infection in the absence of interleukin-10. Immunology. 2000, 100 (4): 494-501. 10.1046/j.1365-2567.2000.00053.x.CrossRefPubMedPubMedCentral
58.
Jacobs M, Fick L, Allie N, Brown N, Ryffel B: Enhanced immune response in Mycobacterium bovis bacille calmette guerin (BCG)-infected IL-10-deficient mice. Clin Chem Lab Med. 2002, 40 (9): 893-902. 10.1515/CCLM.2002.158.CrossRefPubMed
59.
Roach TI, Barton CH, Chatterjee D, Liew FY, Blackwell JM: Opposing effects of interferon-gamma on iNOS and interleukin-10 expression in lipopolysaccharide- and mycobacterial lipoarabinomannan-stimulated macrophages. Immunology. 1995, 85 (1): 106-113.PubMedPubMedCentral
60.
Chung EY, Liu J, Homma Y, Zhang Y, Brendolan A, Saggese M, Han J, Silverstein R, Selleri L, Ma X: Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity. 2007, 27 (6): 952-964. 10.1016/j.immuni.2007.11.014.CrossRefPubMedPubMedCentral
61.
Devadoss P, Klegerman ME, Groves MJ: Surface morphology of Mycobacterium bovis BCG: relation to mechanisms of cellular aggregation. Microbios. 1991, 65 (263): 111-125.PubMed
62.
Gough PJ, Gordon S: The role of scavenger receptors in the innate immune system. Microbes Infect. 2000, 2 (3): 305-311. 10.1016/S1286-4579(00)00297-5.CrossRefPubMed
63.
Court N, Vasseur V, Vacher R, Fremond C, Shebzukhov Y, Yeremeev VV, Maillet I, Nedospasov SA, Gordon S, Fallon PG, et al: Partial redundancy of the pattern recognition receptors, scavenger receptors, and C-type lectins for the long-term control of Mycobacterium tuberculosis infection. J Immunol. 184 (12): 7057-7070. 10.4049/jimmunol.1000164.
64.
Doz E, Rose S, Nigou J, Gilleron M, Puzo G, Erard F, Ryffel B, Quesniaux VF: Acylation determines the toll-like receptor (TLR)-dependent positive versus TLR2-, mannose receptor-, and SIGNR1-independent negative regulation of pro-inflammatory cytokines by mycobacterial lipomannan. J Biol Chem. 2007, 282 (36): 26014-26025. 10.1074/jbc.M702690200.CrossRefPubMed
65.
Gowda DC: TLR-mediated cell signaling by malaria GPIs. Trends Parasitol. 2007, 23 (12): 596-604. 10.1016/j.pt.2007.09.003.CrossRefPubMed
66.
Fortune SM, Solache A, Jaeger A, Hill PJ, Belisle JT, Bloom BR, Rubin EJ, Ernst JD: Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms. J Immunol. 2004, 172 (10): 6272-6280.CrossRefPubMed
67.
Banaiee N, Kincaid EZ, Buchwald U, Jacobs WR, Ernst JD: Potent inhibition of macrophage responses to IFN-gamma by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2. J Immunol. 2006, 176 (5): 3019-3027.CrossRefPubMed
68.
Noss EH, Pai RK, Sellati TJ, Radolf JD, Belisle J, Golenbock DT, Boom WH, Harding CV: Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J Immunol. 2001, 167 (2): 910-918.CrossRefPubMed
69.
Weiss DJ, Souza CD, Evanson OA, Sanders M, Rutherford M: Bovine monocyte TLR2 receptors differentially regulate the intracellular fate of Mycobacterium avium subsp. paratuberculosis and Mycobacterium avium subsp. avium. J Leukoc Biol. 2008, 83 (1): 48-55. 10.1189/jlb.0707490.CrossRefPubMed
70.
Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT, Woodgett JR, Ivashkiv LB: IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity. 2006, 24 (5): 563-574. 10.1016/j.immuni.2006.02.014.CrossRefPubMed
71.
Yamamoto N, Ikeda H, Tandon NN, Herman J, Tomiyama Y, Mitani T, Sekiguchi S, Lipsky R, Kralisz U, Jamieson GA: A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka-platelets lack detectable GPIV (CD36). Blood. 1990, 76 (9): 1698-1703.PubMed
72.
Curtis BR, Aster RH: Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians. Transfusion. 1996, 36 (4): 331-334. 10.1046/j.1537-2995.1996.36496226147.x.CrossRefPubMed
73.
Tomiyama Y, Take H, Ikeda H, Mitani T, Furubayashi T, Mizutani H, Yamamoto N, Tandon NN, Sekiguchi S, Jamieson GA, et al: Identification of the platelet-specific alloantigen, Naka, on platelet membrane glycoprotein IV. Blood. 1990, 75 (3): 684-687.PubMed
74.
75.
Aitman TJ, Cooper LD, Norsworthy PJ, Wahid FN, Gray JK, Curtis BR, McKeigue PM, Kwiatkowski D, Greenwood BM, Snow RW, et al: Malaria susceptibility and CD36 mutation. Nature. 2000, 405 (6790): 1015-1016. 10.1038/35016636.CrossRefPubMed
76.
Fry AE, Ghansa A, Small KS, Palma A, Auburn S, Diakite M, Green A, Campino S, Teo YY, Clark TG, et al: Positive selection of a CD36 nonsense variant in sub-Saharan Africa, but no association with severe malaria phenotypes. Hum Mol Genet. 2009, 18 (14): 2683-2692. 10.1093/hmg/ddp192.CrossRefPubMedPubMedCentral
Metadata
Title
CD36 deficiency attenuates experimental mycobacterial infection
Authors
Michael Hawkes
Xiaoming Li
Maryanne Crockett
Angelina Diassiti
Constance Finney
Gundula Min-Oo
W Conrad Liles
Jun Liu
Kevin C Kain
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-299

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue

Research article

Prevalence, concordance and determinants of human papillomavirus infection among heterosexual partners in a rural region in central Mexico

Research article

Risk of latent TB infection in individuals employed in the healthcare sector in Germany: a multicentre prevalence study

Research article

Mapping the risk of avian influenza in wild birds in the US

Research article

Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia

Research article

Bacteremic community-acquired pneumonia due to Klebsiella pneumoniae: Clinical and microbiological characteristics in Taiwan, 2001-2008

Research article

Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits